- Aurora S, Dodick D, Turkel C, et al. Onabotulinumtoxin. A for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793-803. doi:10.1177/0333102410364676 (last accessed 19 September 2024)
- Chebini, A., Marzoughi, S., Randhawa, J., Guh, D., Wiseman, S., Fedoroff, I., & Ong, M. (2021). The Effects of a Multiday (10–14 days) Subanesthetic Dose IV Ketamine Infusion in the Treatment of Refractory Chronic Pain. Pain Management, 12(3), 337–346. https://doi.org/10.2217/pmt-2021-0064 (last accessed 19 September 2024)
- Marzoughi, S., Ripsman, D., & Ong, M. (2023). Therapeutic Effects of 7- to 14-Day Subanesthetic Ketamine Infusions for Chronic Pain on Standardized Psychiatric Measures. Pain Management, 13(9), 529–538. https://doi.org/10.2217/pmt-2023-0066 (last accessed 19 September 2024)
Other noteworthy articles on complex, refractory chronic pain:
- R. Douglas Fields. New Culprits In Chronic Pain. Scientific American, Vol. 301, No. 5 (November 2009), pp. 50-57
- Zekry, O., Gibson, S. B., & Aggarwal, A. (2016). Subanesthetic, Subcutaneous Ketamine Infusion Therapy in the Treatment of Chronic Nonmalignant Pain. Journal of Pain & Palliative Care Pharmacotherapy, 30(2), 91–98 https://doi.org/10.3109/15360288.2016.1161690 (last accessed 19 September 2024)
- Malcangio, Marzia. Microglia and chronic pain. PAIN 157(5):p 1002-1003, May 2016. | DOI: 10.1097/j.pain.0000000000000509 (last accessed 19 September 2024)
